In conclusion, the combination of BGT226 (a PI3K/mTOR inhibitor) and STA9090 (an HSP90 inhibitor) is effective in multiple preclinical models of ACC at clinically achievable concentrations warranting further clinical studies. The gene discussed is PIK3CG; the disease is adrenal cortex carcinoma.